PBAC's latest decision on Abrocitinib: Recommended with restriction (2024). Considered for Treatment of adult patients with chronic severe atopic dermatitis who are unable to achieve disease control with daily use of topical treatments for at least 28 days.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults aged 18 years or older with chronic severe atopic dermatitis affecting the whole body or face/hands, with PGA score ≥4 and EASI score ≥20 despite daily topical therapy (corticosteroid of medium to high potency or calcineurin inhibitor) for at least 28 days.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Comparator
dupilumab
Economic model
CUA
ICER note
Cost-minimisation analysis for ABRO 200 mg versus dupilumab; cost-effectiveness analysis for ABRO 100 mg versus dupilumab. No numeric ICER stated in public text.